BioSpace News Archive

The State of California is considering a measure to sell its own brand of generic drugs in an effort to get in on those cost-savings. California’s Gov. Gavin Newsom is expected to reveal the scheme today in his new state budget.

Not waiting for the start of the annual J.P. Morgan Healthcare Conference, Eli Lilly announced it will acquire California-based Dermira, Inc. in an all-cash deal for $1.1 billion.

With a new year underway, the U.S. Food and Drug Administration is doing some house-cleaning of sorts.

As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.

Moderna Therapeutics is inching closer to becoming a commercial company and the company sees a potential blockbuster in an experimental treatment.

Behavioral interviewing is probably the most popular interviewing style utilized today. Keeping this in mind we have listed some behavioral interview questions for you.

Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche. Under the terms of the deal, Roche will pay Amunix $40 million upfront.

Late Thursday, the U.S. Food and Drug Administration approved a new therapy to treat a rare mutation in patients with gastrointestinal stromal tumors.

The first full business week of the new year began with plenty of clinical trial news. Here’s a look.

Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2019